Tevogen reports PredicTcell Beta recall at 92% and precision at 48%

Reuters03-14
Tevogen reports PredicTcell Beta recall at 92% and precision at 48%

Tevogen said beta testing of its PredicTcell model showed recall rising to 92% from 87%, a 5 percentage point increase. Precision increased to 48% from 40%, an 8 percentage point gain. Tevogen said the current version is trained on 1.8 million data points. The company said it has built a proprietary database of more than 655 million peptide sequences and analyzes 37 million scientific publications. Tevogen said Tevogen.AI operates three production AI agents that continuously evaluate 14 active peptide candidates.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603131230PRIMZONEFULLFEED9671778) on March 13, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment